New immune combo aims to fight lymphoma without chemo
NCT ID NCT07477366
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug combination for people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The treatment uses three immune-based drugs (CD19 t-haNK, NAI, and rituximab) without chemotherapy. About 20 adults aged 18 to 75 will take part to see if the combination can shrink tumors and improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.